八例HIV阴性浆母细胞淋巴瘤的临床特征与生存分析
回顾性分析北京协和医院1997年1月至2015年5月确诊的8例HIV阴性浆母细胞淋巴瘤患者,中位年龄60岁,均有结外受累,6例为Ann Arbor Ⅳ期。7例接受化疗并规律随访者中位无进展生存15个月,中位总生存36个月;Ⅳ期患者疗效难以维持,预后不良。
要点
- HIV阴性浆母细胞淋巴瘤以中老年为主,临床呈高侵袭性,均出现结外受累,尤其是骨髓。
- 免疫表型弥漫表达CD38和CD138,B细胞标志PAX-5及Bcl-6少见,与浆细胞瘤接近。
- Ⅳ期患者化疗虽有效但疗效难以维持,中位无进展生存10个月,中位总生存12个月。
核心结论
- HIV阴性浆母细胞淋巴瘤以中老年为主,临床呈高侵袭性,均出现结外受累尤其是骨髓,免疫表型与浆细胞瘤较为接近,分期较晚的患者预后不良。
研究设计与样本
- 回顾性分析北京协和医院1997年1月至2015年5月确诊的8例HIV阴性浆母细胞淋巴瘤患者的临床资料,分析临床特征及转归。
主要发现
- 8例中男3例、女5例,中位年龄60(43~80)岁,4例存在导致免疫功能低下的疾病或状态,均有结外受累,6例为Ann Arbor Ⅳ期,5例有骨髓受累。
- 所有患者均弥漫表达CD38和CD138,B细胞标志包括PAX-5及Bcl-6少见;5例检测EBV-DNA均为阴性。
- 接受化疗并规律随访的7例中位随访36(11~57)个月,中位无进展生存15(6~52)个月,中位总生存36(2~52)个月。
- 4例采用硼替佐米联合化疗,3例有效,但疗效难以维持,分别于治疗后2、9、21个月疾病进展。
- 2例Ⅰ~Ⅱ期患者治疗有效,未出现疾病进展,持续存活;5例Ⅳ期患者化疗后有效但疗效难以维持,中位无进展生存10(2~21)个月,中位总生存12(6~52)个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To deepen the knowledge of HIV-negative plasmablastic lymphoma (PBL) . Methods: Medical records from 8 HIV-negative PBL patients diagnosed in Peking Union Medical College Hospital from January 1997 to May 2015 were collected, and the clinical features and prognosis of these patients were analyzed. Results: All of these 8 patients were diagnosed as HIV-negative PBL, 3 of 8 patients were males, and others were female. The median age was 60 (43-80) year. Among these patients, 4 cases had underlying immunosuppressive state. These patients all had extra-nodular involvement, and 6 cases of them were at stage Ⅳ according to Ann Arbor Staging, 5 patients had bone marrow involvement. CD38 and CD138 were diffusely positive for all patients, while the positive rate of B cell marker including PAX-5 and Bcl-6 were relative low. 5 of 8 patients had been detected for EBV-DNA, and all of them were negative. The median follow-up for the 7 patients receiving chemotherapy and regular follow-ups was 36 (11-57) months, the median progression-free survival (PFS) was 15 (6-52) months, and the median overall survival was 36 (2-52) months. Among these patients, 4 cases had received chemotherapy combined with Bortezomib, showing 3 cases of effective, but it seems to be difficult to keep the long term efficacy, and disease progression occurred in 2, 9, and 21 months after treatment. 2 patients at stageⅠ-Ⅱ were treated effectively, without disease progression and survival, 5 patients at stage Ⅳacquired the efficacy unsustainably, with a median PFS of 10 (2-21) months and a median overall survival of 12 (6-52) months. Conclusion: HIV-negative PBL is relatively prevalent in elderly patients, and presenting with high invasiveness in clinical, extremely prone to extra-nodular involvement, especially the bone marrow. The immunophenotype of PBL is more resemble to that of plasmacytoma. Patients who were in late stage at diagnosis show poor prognosis. 目的: 提高对人免疫缺陷病毒(HIV)阴性浆母细胞淋巴瘤的认识。 方法: 回顾性分析北京协和医院1997年1月至2015年5月确诊的8例HIV阴性浆母细胞淋巴瘤患者的临床资料,分析其临床特征及转归。 结果: 8例HIV阴性浆母细胞淋巴瘤中男3例,女5例,中位年龄60(43~80)岁,其中4例存在导致免疫功能低下的疾病或状态。8例患者均有结外受累,2例Ann Arbor分期为Ⅰ~Ⅱ期,6例为Ⅳ期,其中5例有骨髓受累。所有患者均弥漫表达CD38和CD138,B细胞标志包括PAX-5及Bcl-6少见。5例患者进行EBV-DNA检测,均为阴性。接受化疗并规律随访的7例患者中位随访36(11~57)个月,中位无进展生存时间为15(6~52)个月,中位总生存时间为36(2~52)个月;其中4例采用了硼替佐米联合化疗,3例有效,但疗效难以维持,分别于治疗后2、9、21个月疾病进展。2例Ⅰ~Ⅱ期患者均治疗有效,未出现疾病进展,持续存活;5例Ⅳ期患者化疗后虽然有效,但疗效难以维持,中位总生存时间仅12(6~52)个月,中位无进展生存时间仅10(2~21)个月。 结论: 该组HIV阴性浆母细胞淋巴瘤患者以中老年为主,临床呈现高侵袭性,均出现结外(尤其是骨髓)受累,其免疫表型与浆细胞瘤较为接近,分期较晚的患者预后不良。.
引用
- Han X, Hu LX, Ouyang MQ, et al. [Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28468089. doi:10.3760/cma.j.issn.0253-2727.2017.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。